Morning, welcome to the 2026 annual meeting of shareholders of Indivior Pharmaceuticals, Inc. I am pleased to call this meeting to order. This meeting is being conducted in a virtual-only format via live webcast, as disclosed in our proxy statement, to provide shareholders with broad and equitable access to participate regardless of location. We believe this format supports shareholder engagement while ensuring an orderly and efficient meeting. I am David Wheadon, Chair of the Board of Directors of Indivior Pharmaceuticals, Inc. Joining me today are my fellow directors and members of our executive leadership team, all of whom are participating remotely. Also present are representatives of our independent registered public accounting firm and our inspector of election, who will oversee the tabulation and certification of the vote. I will now turn the meeting over to our Company Secretary, Kathryn Hudson, for procedural matters. Thank you, David. Good morning. I am Kathryn Hudson, Company Secretary of Indivior Pharmaceuticals, Inc. Notice of this annual meeting of shareholders was duly given, or notice was duly waived in accordance with the Delaware General Corporation Law and the company's governing documents, as described in the proxy statement filed with the Securities and Exchange Commission on March 27th, 2026. The inspector of election has advised that a quorum is present either in person, virtually, or by proxy, representing a majority of the outstanding shares entitled to vote at this meeting. Accordingly, the meeting is duly constituted and may proceed. This meeting is being conducted through a secure virtual meeting platform. Shareholders may submit questions during the meeting through the online portal. To promote constructive dialogue and ensure that all shareholders have an opportunity to participate, we ask that questions be relevant to the business of the meeting and be stated respectfully. The company reserves the right to group similar questions, limit repetitive inquiries, and exclude questions that are irrelevant to the matters properly before the meeting or that are abusive or inappropriate, all as permitted under Delaware law and consistent with customary public company practice. Only shareholders of record as of the close of business on the record date of March 18th, 2026 are entitled to vote at this meeting. The list of shareholders entitled to vote at the annual meeting is available for examination during the annual meeting by shareholders for any purpose germane to the annual meeting. If you have already submitted your proxy, your shares will be voted as instructed unless you submit a new vote during the meeting. Shareholders participating virtually may vote at any time before the polls are closed by following the instructions on the virtual meeting website. Thank you, Kathryn. We will now proceed to the formal business of the meeting. Each proposal was fully described in the company's proxy statement. I encourage shareholders to review those materials carefully. The first item of business is the election of directors to serve until the next annual meeting of shareholders and until their successors are duly elected and qualified. The nominees for election as directors are those individuals named in proposal one of the proxy statement. The proposal requires the affirmative vote of the majority of the votes cast to elect each director nominee. The second item of business is an advisory vote to approve the compensation of the company's named executive officers, commonly referred to as a say on pay vote, as described in proposal two of the proxy statement. This proposal is advisory in nature and requires the affirmative vote of a majority of the votes present or represented by proxy and entitled to vote on the proposal. The third item of business is an advisory vote on the frequency of future say on pay votes as described in the proposal in proposal three of the proxy statement. Shareholders may indicate whether they prefer that the company hold say on pay votes every one, two, or three years. This proposal is advisory in nature and requires the affirmative vote of a majority of the votes present or represented by proxy and entitled to vote on the proposal. If no frequency receives the foregoing vote, then we will consider the frequency that receives the highest number of affirmative votes cast to be the frequency recommended by our shareholders. The fourth item of business is the ratification of the appointment of PricewaterhouseCoopers as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026, as described in proposal four of the proxy statement. This proposal is advisory in nature and requires the affirmative vote of the majority of the votes present or represented by proxy entitled to vote on the proposal. Are there any comments on the foregoing proposals? Hearing none. The time is 10:06 A.M. Eastern Daylight Time. I declare the polls now open for each matter to be voted on today, May 13th, 2026. Voting on all proposals will remain open for a brief period to allow shareholders participating virtually to submit their votes. Polls are about to close. The polls are now closed at 10:07 A.M. Eastern Daylight Time on May 13th, 2026. The inspector of election has advised that each of the nominees has been elected as a director. Proposals two and four have each received a sufficient approval based on preliminary voting results, and an annual frequency for future advisory votes on executive compensation has been approved. Final voting results will be reported in a current report on Form 8-K to be filed with the Securities and Exchange Commission within four business days. We will now address shareholder questions submitted through the virtual meeting platform. As noted earlier, we will address questions that are relevant to the business of the meeting and that comply with our rules of conduct. If multiple questions address similar topics, we may group them together. Seeing no questions, this concludes our meeting, which is adjourned. We thank you for your continued interest in Indivior Pharmaceuticals, Inc., please have a great day. That concludes our meeting today. You may now disconnect.